Trial
|
Studied treatment |
Control |
Patients |
Size |
Study type
|
Results |
NCT |
Diabetes type 2 - insulin secretagogues in all type of patients - insulin secretagogues - sulfonylureas in all type of patients - antidiabetic drugs in all types of patients - antidiabetic drugs in patients inadequately controlled on monotherapy - antidiabetic drugs in patients inadequately controlled on metformin |
Draeger, 1996 | glimepiride | glibenclamide | | 1044 (524/520) | Confirmatory | | |
Protocol 311 | glimepiride | glibenclamide | | 852 (427/425) | | | |
Charpentier (301F) | glimepiride | gliclazide | | 203 (96/107) | | | |
Inukai, 2005 | glimepiride | gliclazide or glibenclamide | | 172 | | | |
Clark (301), 1997 | glimepiride | glipizide | | 652 (444/208) | | | |
Dills, 1996 | glimepiride | glyburide | | 577 (289/288) | Exploratory | | |
Kaneko, 1993 | glimepiride | placebo | | 93 (62/31) | | | |
Luis Bautista, 2003 | glimepiride | placebo | | NA | | | |
Rosenstock, 1996 | glimepiride | placebo | | 416 | | | |
Schade, 1998 | glimepiride | placebo | | 249 (123/126) | | | |
Study 201 (Goldberg), 1996 | glimepiride | placebo | | 304 | Exploratory | | |
Study 202 | glimepiride | placebo | | 247 (122/125) | | | |
Riddle, 1994 | glimepiride | placebo (add on insulin) | | 145 (72/73) | | | |
LEAD-2 (Nauck) Sulf vs pbo, 2009 | glimepiride | placebo (add on MET) | | NA | | | NCT00318461 |
Charpentier, 2001 | glimepiride | placebo (add on MET) | | NA | | | |
Sonnenberg, 1997 | glimepiride od | glimepiride bid | | 98 (50/48) | | | |